Volume 10, Number 3—March 2004
Synopsis
Reemerging Leptospirosis, California
Elissa Meites*, Michele T. Jay†, Stanley Deresinski†‡, Wun-Ju Shieh§, Sherif R. Zaki§, Lucy Tompkins*, and D. Scott Smith*¶
Table 2
Acute- and convalescent-phase serologic and microscopy diagnosis of leptospirosis by MAT,a IgM-ELISA, IHA, and IHC assay in California case reportsb
| Case | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Days post exposure |
9 |
11 |
15 |
32 |
21 |
36 |
23 |
44 |
Acute |
conv |
|
| MAT |
ND |
ND |
Neg |
1:3200 |
Neg |
1:800 |
1:800 |
1:200 |
Neg |
ND |
|
| ELISA |
ND |
ND |
Neg |
Pos |
Pos |
ND |
Pos |
ND |
Pos |
ND |
|
| IHA |
1:50 |
1:800 |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
1:200 |
|
| IHC assay | NA | NA | NA | Pos | Pos | ||||||
aMAT, microagglutination test. Highest MAT titer reported to any leptospira serogroup.
bIgM-ELISA, immunoglobulin M–Enzyme-Linked ImmunoSorbent Assay; IHA, indirect hemagluttination assay; IHC, immunohistochemical; NA: not available; ND: not done.
Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.